Log in to save to my catalogue

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1525767972

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

About this item

Full title

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Publisher

Waltham, MA: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2014-05, Vol.370 (20), p.1879-1888

Language

English

Formats

Publication information

Publisher

Waltham, MA: Massachusetts Medical Society

More information

Scope and Contents

Contents

In previously untreated patients with HCV genotype 1 infection without cirrhosis, the rate of sustained virologic response was 94% with 8 weeks of ledipasvir–sofosbuvir, 93% with 8 weeks of ledipasvir–sofosbuvir plus ribavirin, and 95% with 12 weeks of ledipasvir–sofosbuvir.
More than 3 million people in the United States are chronically infecte...

Alternative Titles

Full title

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1525767972

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1525767972

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1402355

How to access this item